Table 3 Distribution of CYP2C19 polymorphisms in MACE, no-MACE, bleeding, and no-bleeding patients
Variables | Overall (n = 351) | MACE (n = 101) | No-MACE (n = 250) | P value | Bleeding (n = 18) | No-bleeding (n = 333) | P value |
|---|---|---|---|---|---|---|---|
Polymorphisms, n (%) | |||||||
CYP2C19*2 | Â | Â | Â | Â | Â | Â | Â |
 GG | 251 (71.5) | 58 (57.4) | 193 (77.2) | 0.001* | 16 (88.9) | 235 (70.6) | 0.273 |
 GA | 90 (25.6) | 38 (37.6) | 52 (20.8) | 2 (11.1) | 88 (26.4) | ||
 AA | 10 (2.9) | 5 (5.0) | 5 (2.0) | / | 10 (3.0) | ||
 A allele | 110 (15.7) | 48 (23.8) | 62 (12.4) |  < 0.001* | 2 (5.6) | 108 (16.2) | 0.139 |
 G allele | 692 (84.3) | 154 (76.2) | 438 (87.6) | 34 (94.4) | 558 (83.8) | ||
CYP2C19*3 | Â | Â | Â | Â | Â | Â | Â |
 GG | 328 (93.4) | 91 (90.1) | 237 (94.8) | 0.107 | 16 (88.9) | 312 (93.7) | 0.333 |
 GA | 23 (6.6) | 10 (9.9) | 13 (5.2) | 2 (11.1) | 21 (6.3) | ||
 AA | / | / | / | / | / |  | |
 A allele | 23 (3.3) | 10 (5.0) | 13 (2.6) | 0.113 | 2 (5.6) | 21 (3.2) | 0.332 |
 G allele | 679 (96.7) | 192 (95.0) | 487 (97.4) | 34 (94.4) | 645 (96.8) | ||
CYP2C19*17 | Â | Â | Â | Â | Â | Â | Â |
 CC | 252 (71.8) | 81 (80.2) | 171 (68.4) | 0.08 | 10 (55.6) | 242 (72.7) | 0.139 |
 CT | 91 (25.9) | 18 (17.8) | 73 (29.2) | 7 (38.9) | 84 (25.2) | ||
 TT | 8 (2.3) | 2 (2.0) | 6 (2.4) | 1 (5.6) | 7 (2.1) | ||
 T allele | 107 (15.2) | 22 (10.9) | 85 (17.0) | 0.041* | 9 (25.0) | 98 (14.7) | 0.094 |
 C allele | 595 (84.8) | 180 (89.1) | 415 (83.0) | 27 (75.0) | 568 (85.3) | ||
Metabolizer Phenotype, n (%) | |||||||
 EMs | 147 (41.9) | 37 (36.6) | 110 (41.6) | 0.205 | 7 (38.9) | 140 (42.0) | 0.792 |
 IMs | 107 (30.5) | 43 (42.6) | 64 (25.6) | 0.002* | 4 (22.2) | 103 (30.9) | 0.601 |
 PMs | 12 (3.4) | 7 (6.9) | 5 (2.0) | 0.021* | / | 12 (3.6) | 1.0 |
 UMs | 85 (24.2) | 14 (13.9) | 71 (28.4) | 0.004* | 7 (38.9) | 78 (23.4) | 0.158 |